

Exhibit B

Exhibit B**Summary of Generic Entry**

		Generic Equivalents									
		1st	2nd	3rd	4th	5th	6th	7th	8th	9th	10th
Blenoxane		Pharmacia/ Pfizer Jul-96		Mayne Apr-00	Sicor Aug-00	Bedford Mar-03					
Cytoxan		Neosar Pharmacia Nov-83		Wyeth Apr-88	Baxter Jun-04						
Cytoxan Tablet		Roxane Apr-00									
Etopophos*											
Paraplatin		Company Launch Date	Sicor Jul-04	Bedford Oct-04	BMS Oct-04	American Pharma Oct-04	Mayne Oct-04	Baxter Nov-04	Pliva Mar-05	Cura Pharma Aug-05	
Rubex **		Company Launch Date	Bedford Apr-89	Rubex BMS** May-89	Unknown Oct-89	Astrazeneca Jul-90	Pharmacia Apr-91	Sicor Oct-95	American Pharma Feb-96	Private Label Aug-99	Baxter Jan-01
Taxol		Company Launch Date	Onxo/ Ivax Nov-00	Mylan Aug-01	Bedford Sep-01	Mayne May-02					
VePesid*		Company Launch Date	Sicor Feb-94	Toposar Pharmacia/ Pfizer May-95	Bedford Nov-95	Hospira Mar-96	Astrazeneca Apr-96	Supergen Jul-96	Watson Dec-96	Marsam Pharma Aug-98	American Pharma Apr-00
VePesid Capsule		Company Launch Date	Mylan Nov-01	Unit Dose Lab Nov-01							Baxter Dec-00

Sources: IMS sales data

Notes:

* Etopophos, which did not face generic competition, and injectable etoposide are reimbursed under the same J-codes (J9181 and J9182).

** Rubex is a branded generic version of Pharmacia's Adriamycin, which was originally approved in 1974. Rubex was marketed by Immunex Corporation in 1992 and 1993 and by BMS thereafter.

Defendants' Exhibit

2637

01-12257 - PBS